Literature DB >> 16417238

Importance of the EP(1) receptor in cutaneous UVB-induced inflammation and tumor development.

Kathleen L Tober1, Traci A Wilgus, Donna F Kusewitt, Jennifer M Thomas-Ahner, Takayuki Maruyama, Tatiana M Oberyszyn.   

Abstract

Chronic exposure to UV light, the primary cause of skin cancer, results in the induction of high levels of cyclooxygenase-2 (COX-2) expression in the skin. The involvement of COX-2 in the carcinogenesis process is mediated by its enzymatic product, prostaglandin E(2) (PGE(2)). PGE(2) has been shown to have a variety of activities that can contribute to tumor development and growth. The effects of PGE(2) on different cell types are mediated by four E prostanoid (EP) receptors, EP(1)-EP(4). While recent studies have demonstrated the importance of EP(1) in the development of colon and breast cancer, the extent of EP(1) involvement in the cutaneous photocarcinogenesis process is unknown. This study found that topical treatment with celecoxib or the specific EP(1) antagonist ONO-8713 decreased acute UVB-induced inflammation in the skin and significantly reduced the number of tumors per mouse following 25 weeks of UVB exposure and topical treatment. This study suggests that drugs designed to block EP(1) may have the potential to be used as anti-inflammatory and/or chemopreventive agents that reduce the risk of skin cancer development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16417238     DOI: 10.1038/sj.jid.5700014

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  35 in total

1.  UV radiation inhibits 15-hydroxyprostaglandin dehydrogenase levels in human skin: evidence of transcriptional suppression.

Authors:  Benjamin L Judson; Akira Miyaki; Vikram D Kekatpure; Baoheng Du; Patricia Gilleaudeau; Mary Sullivan-Whalen; Arash Mohebati; Sudhir Nair; Jay O Boyle; Richard D Granstein; Kotha Subbaramaiah; James G Krueger; Andrew J Dannenberg
Journal:  Cancer Prev Res (Phila)       Date:  2010-07-19

Review 2.  Prostaglandin E2 EP receptors as therapeutic targets in breast cancer.

Authors:  Jocelyn Reader; Dawn Holt; Amy Fulton
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

3.  Prostaglandin E2 activates the mTORC1 pathway through an EP4/cAMP/PKA- and EP1/Ca2+-mediated mechanism in the human pancreatic carcinoma cell line PANC-1.

Authors:  Hui-Hua Chang; Steven H Young; James Sinnett-Smith; Caroline Ei Ne Chou; Aune Moro; Kathleen M Hertzer; Oscar Joe Hines; Enrique Rozengurt; Guido Eibl
Journal:  Am J Physiol Cell Physiol       Date:  2015-08-26       Impact factor: 4.249

4.  The EP1 receptor for prostaglandin E2 promotes the development and progression of malignant murine skin tumors.

Authors:  Inok Surh; Joyce E Rundhaug; Amy Pavone; Carol Mikulec; Erika Abel; Melissa Simper; Susan M Fischer
Journal:  Mol Carcinog       Date:  2011-07-07       Impact factor: 4.784

5.  Expression of prostaglandin E2 receptor subtypes in human pterygium and normal conjunctiva: immunohistochemical study.

Authors:  Erdem Dinç; Özer Dursun; Banu Yılmaz; Mustafa Vatansever; A Ayça Sarı; Özlem Yıldırım; Ufuk Adıgüzel
Journal:  Int Ophthalmol       Date:  2017-07-10       Impact factor: 2.031

6.  Caffeic acid, a phenolic phytochemical in coffee, directly inhibits Fyn kinase activity and UVB-induced COX-2 expression.

Authors:  Nam Joo Kang; Ki Won Lee; Bong Jik Shin; Sung Keun Jung; Mun Kyung Hwang; Ann M Bode; Yong-Seok Heo; Hyong Joo Lee; Zigang Dong
Journal:  Carcinogenesis       Date:  2008-12-10       Impact factor: 4.944

7.  Celecoxib reduces the effects of acute and chronic UVB exposure in mice treated with therapeutically relevant immunosuppressive drugs.

Authors:  Brian C Wulff; Jennifer M Thomas-Ahner; Jonathan S Schick; Tatiana M Oberyszyn
Journal:  Int J Cancer       Date:  2010-01-01       Impact factor: 7.396

8.  Concurrent targeting of eicosanoid receptor 1/eicosanoid receptor 4 receptors and COX-2 induces synergistic apoptosis in Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus associated non-Hodgkin lymphoma cell lines.

Authors:  Arun George Paul; Bala Chandran; Neelam Sharma-Walia
Journal:  Transl Res       Date:  2013-03-20       Impact factor: 7.012

Review 9.  Prostanoid receptor antagonists: development strategies and therapeutic applications.

Authors:  R L Jones; M A Giembycz; D F Woodward
Journal:  Br J Pharmacol       Date:  2009-07-15       Impact factor: 8.739

10.  The tumor promoting activity of the EP4 receptor for prostaglandin E2 in murine skin.

Authors:  Melissa S Simper; Joyce E Rundhaug; Carol Mikulec; Rebecca Bowen; Jianjun Shen; Yue Lu; Kevin Lin; Inok Surh; Susan M Fischer
Journal:  Mol Oncol       Date:  2014-07-03       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.